Cytokine function in medication-naive first episode psychosis: A systematic review and meta-analysis

Upthegrove, Rachel, Manzanares-Teson, Nuria, Barnes, Nicholas M.·2014·Schizophrenia Research
DOI 10.1016/j.schres.2014.03.005

Cited by (501)

Items 401–500 of 501

  1. Búsqueda De Nuevos Biomarcadores De La Cognición En Esquizofrenia
    Rafael Penadés, Clemente García‐Rizo, Miquel Bioque, Alexandre González-Rodríguez, Bibiana Cabrera, Gisela Mezquida, Miquel Bernardo · 2015 · Schizophrenia Research Cognition
  2. Proteomic Studies of Psychiatric Disorders
    Paul C. Guest · 2018 · Methods in molecular biology
  3. Cortisol and cytokines in early psychosis, do they correlate? A scoping review
    Evangelos Karanikas · 2019 · Neurology Psychiatry and Brain Research
  4. Cytokines as Biomarkers in Psychiatric Disorders: Methodological Issues
    Olfa Khalfallah, Susana Barbosa, Emanuela Martinuzzi, Laëtitia Davidovic, Nicolas Glaichenhaus · 2021 · Springer eBooks
  5. Electroconvulsive therapy in a patient with positive anti-NMDA receptor antibodies presenting with isolated psychiatric symptoms: A case report
    Lu Yuan, Arui Tan, Jun Zhang · 2021 · Schizophrenia Research
  6. Reduced Serum Levels of Soluble Interleukin-15 Receptor α in Schizophrenia and Its Relationship to the Excited Phenotype
    Yi He, Qijing Bo, Zhen Mao, Jian Yang, Min Liu, Haixia Wang, Abba J. Kastin, Weihong Pan, Chuanyue Wang, Zuoli Sun · 2022 · Frontiers in Psychiatry
  7. From co-morbidity to transdiagnostic potential and novel immunotherapies for psychosis
    Rachel Upthegrove · 2022 · Psychiatry Research
  8. A Matched Case-Control Study of the Serum Level and Gene Expression of IL-6 and IL-12 in Patients with Schizophrenia Spectrum Disorder: An Azeri Acute Phase/Recent-Onset Psychosis Survey (ARAS) Study
    Ali Reza Shafiee‐Kandjani, Morteza Asadi, Sara Farhang, Dariush Shanebandi, Milad Asadi, Arash Mohagheghi, Richard Bruggeman · 2024 · Archives of Neuroscience
  9. Transcriptomic and epigenomic consequences of heterozygous loss of function mutations in AKAP11 , the first large-effect shared risk gene for bipolar disorder and schizophrenia
    Nargess Farhangdoost, Calwing Liao, Yumin Liu, Martin Alda, Patrick A. Dion, Guy Armand Rouleau, Anouar Khayachi, Boris Chaumette · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
  10. Reprint of: Internalising symptoms mediate the longitudinal association between childhood inflammation and psychotic-like experiences in adulthood
    Marta Francesconi, Amedeo Minichino, Golam Mohammed Khandaker, Emily Midouhas, Glyn Lewis, Eirini Flouri · 2020 · Schizophrenia Research
  11. The kynurenine pathway of tryptophan catabolism and schizophrenia
    Miloš Marković, Tatjana Nikolić, Sanja Totić-Poznanović · 2023 · Medicinski podmladak
  12. The psychoneuroimmunology of Psychosis: Peeking past the clouds of Heterogeneity: Editorial
    Rachel Upthegrove, David R. Goldsmith · 2024 · Brain Behavior and Immunity
  13. Shared and unique therapeutic targets of KarXT and clozapine for schizophrenia treatment revealed by network pharmacology and molecular docking analyses: Implications for differential clinical responses
    Chuanjun Zhuo, Chao Li, Hongjun Tian, Lina Wang, Xiaoyan Ma, Ranli Li, Ximing Chen, Yachen Li, Qiuyu Zhang, Lei Yang · 2025 · Neurotherapeutics
  14. Recent cannabis use affects the association between baseline immune markers and long-term outcomes in psychosis
    Isabel Viola Kreis, Kristin Fjelnseth Wold, Gina Åsbø, Camilla Bärthel Flaaten, Magnus Johan Engen, Siv Hege Lyngstad, Line Hustad Widing, Mashhood Ahmed Sheikh, Maren Caroline Frogner Werner, Eivind Bakken et al. · 2025 · Translational Psychiatry
  15. Systemic inflammatory and oxidative stress alterations in recent-onset psychosis: findings from a non-smoking case-control sample
    Daphne A M Dielemans, Julia M. Hagen, Arjen L. Sutterland, Arno R. Bourgonje, Hanno L. Tan, Harry van Goor, René Lutter, Nico J.M. van Beveren, Anja Lok, Lieuwe de Haan · 2025 · Psychiatry Research
  16. Neuropharmacological targets for schizophrenia treatment: An update
    Caroline Araújo Costa de Lima, Marta Eduarda Oliveira Barbosa, Fábio José Coelho de Souza-Júnior, Sarah Viana Farias, Enéas Andrade Fontes-Júnior, Cristiane do Socorro Ferraz Maia · 2025 · Progress in Neuro-Psychopharmacology and Biological Psychiatry
  17. Cytokine changes in clinical high risk for psychosis population following antipsychotic medication
    Yanyan Wei, LiHua Xu, D. H. Zhang, Jiahui Zeng, XiaoChen Tang, ZhengHui Yi, HaiChun Liu, MingLiang Ju, HuiRu Cui, Yingying Tang et al. · 2026 · Translational Psychiatry
  18. The role of 5-HT3 receptors in schizophrenia and associated depressive and addictive comorbidities
    Radomír Jůza, Anna Więckowska, Iveta Vojtěchová, Kamil Kuča, Ondřej Soukup, Jan Korábečný, Tomáš Petrásek · 2026 · Progress in Neuro-Psychopharmacology and Biological Psychiatry
  19. Relationship of Serum Tricellulin, MarvelD3, and Tumor Necrosis Factor-Alpha Levels With Obsessive-Compulsive Disorder Severity in Children and Adolescents
    Kübranur Ünal, Yasemin Taş Torun, Mehmet Emre Erol, Zeynep Kübra Kurt, Cansu Özbaş · 2026 · Journal of korean Academy of Child and Adolescent Psychiatry
  20. Biochemical markers in first-episode psychosis: A case-control study
    Ritwik Mishra, Surender Sharma, Shashivadhanan Sundaravadhanan, MD Niyaz, Ankit Singal, Gurpreet Singh Bhalla, Neha Sharma · 2026 · Medical Journal Armed Forces India
  21. Machine learning for immune biomarkers in severe mental illness: a systematic review
    Rayan Slatni, Federica Colombo, Paolo Enrico, Igor Branchi, Livia De Picker, Benedetta Vai · 2026 · Neuroscience Applied
  22. Biomarkers for Predicting Clinical Deterioration in Schizophrenia-Spectrum Disorders: A Systematic Review
    Valerio Ricci, Alessandro Sarni, Marialuigia Barresi, Lorenzo Remondino, Giovanni Martinotti, Giuseppe Maina · 2026 · Brain Sciences
  23. The Immune and Metabolic Factors of Schizophrenia
    Kumlesh Kumar Dev, Kara E. O’Connell · 2014
  24. Effectiveness of Immunotherapies for Psychotic Disorders
    Rachel Upthegrove, J.F.W. Deakin · 2021 · Cambridge University Press eBooks
  25. Complement Activation Products in Patients with Chronic Schizophrenia
    Krzysztof Rudkowski, Katarzyna Waszczuk, Ernest Marek Tyburski, Katarzyna Rek-Owodziń, Piotr Plichta, Piotr Podwalski, Maksymilian Bielecki, Monika Mak, Anna Michalczyk, Maciej Tarnowski et al. · 2023 · Journal of Clinical Medicine
  26. The Role of Interleukin-6 in the Pathological Mechanisms of Schizophrenia
    Grigory V. Rukavishnikov, Tatyana Vladimirovna Zhilyaeva, E. E. Dubinin, Galina Elevna Mazo · 2023 · Neurochemical Journal
  27. Pilot Study to Detect the Repertoires of T-Cell Receptor Gamma Chains in Patients with Juvenile Schizophrenia
    Maria Yu. Plotnikova, A. D. Patrikeev, Аnastasia Levchenko, Olga Y. Fedorenko, Т. В. Андреева, Evgeny Ivanovich Rogaev · 2023 · Russian Journal of Genetics
  28. Роль синаптического прунинга в этиологии шизофрении
    Nikolai Kondratev, Вера Евгеньевна Голимбет · 2016 · Psikhiatriya
  29. Interleukin-6 Role in Schizophrenia Pathological Mechanisms
    Grigory V. Rukavishnikov, Tatyana Vladimirovna Zhilyaeva, Е. Е. Дубинина, Galina Elevna Mazo · 2023 · Нейрохимия
  30. The role of immuno-inflammatory factors in the development of negative symptoms in schizophrenia
    A.A. Moritz, P. S. Terebova, Mikhail V. Ivanov · 2024 · S S Korsakov Journal of Neurology and Psychiatry
  31. Association of Serum SOCS3 and Inflammatory Marker Levels With Cognitive Function in First‐Episode Schizophrenia
    Jiali Luo, Junjiao Ping, Jing Wan, Jianli Zhu, Ying Zhang, Jie Zhang, Tingyun Jiang · 2025 · International Journal of Developmental Neuroscience
  32. Prednisolone add-on in early phase schizophrenia: A randomized, double-blind, placebo-controlled pilot study
    Gunnhild E. Hoprekstad, Erik Johnsen, Christoffer Andreas Bartz-Johannessen, Jill Bjarke, Petros Drosos, Ole Bernt Fasmer, Kristian Varden Gjerde, Solveig Klæbo Reitan, Silje Skrede, Iris E. Sommer et al. · 2025 · Brain Behavior & Immunity - Health
  33. Malaria in Pregnancy: An Unrecognized Risk Factor for Neuropsychiatric Disease in Offspring?
    Vanessa Tran, Andrea M. Weckman, Kevin C. Kain · 2016 · Pediatric Infectious Diseases Open Access
  34. Comorbid Psychiatric Illnesses
    Einar Thorsteinsson, Rhonda Frances Brown · 2019 · Springer eBooks
  35. Molecular Imaging
    Simon Červenka, Lars Farde · 2020 · Springer eBooks
  36. Effect of Probiotics on the Traumatic Brain Injury
    Emine Müge KARAKAYALI, Erdoğan Kocamaz, Şüheda Alpay, Tuna Önal, Mustafa Öztatlıcı, Rabia DURUŞMA, Hasan Fehmi Özel, Mesut Mete, Necíp Kutlu, Mehmet İbrahim Tuğlu · 2022 · Forbes Journal of Medicine
  37. THE ROLE OF CYTOKINES IN SCHIZOPHRENIA
    Iva Binić, Jovana Petrović, Jovana Antonijević, Dimitrije Pančić, Maša Golubović, Filip Petrović, Jelena Branković, Olivera Žikić · 2023 · Acta Medica Medianae
  38. Heterogeneity of research results: New perspectives on psychological science
    Audrey Helen Linden · 2019 · Northumbria Research Link (Northumbria University)
  39. Inflammation-Schizophrenia: A Bidirectional Causal Association Mediated by Cytokines
    Ahmad Shamabadi, Shahin Akhondzadeh · 2022 · Avicenna Journal of Medical Biotechnology
  40. Project 1: investigating the polyclonal nature of Glioblastoma through the development of a 3-dimensional spheroid model And Project 2: Investigating TNF-α in first episode psychosis medication naïve schizophrenia patients to demographically controlled individuals and pharmacological manipulation of TNF-α release
    Katherine L. Eales · 2014 · University of Birmingham Institutional Research Archive (University of Birmingham)
  41. Blood-based Biomarkers for Personalised Medicine Applications in Schizophrenia
    Jakub Tomasik · 2014 · EUR Research Repository (Erasmus University Rotterdam)
  42. Assessment the Serum Level of IL6, IL10 versus Neuregulin 1 among Schizophrenic Patients in Iraq
    Manal Mohammed Khadhim · 2017 · Journal of Medical Science And clinical Research
  43. Psycho-neuro-immuno-endocrinology of schizophrenia: Back to the future
    Rajiv Tandon, Uma Suryadevara · 2017 · Asian Journal of Psychiatry
  44. PET studies on the immune cell marker TSPO in first episode psychosis patients
    Karin Collste · 2017 · Figshare
  45. High genetic loading of schizophrenia predicts poor response to lithium in patients with bipolar disorder: A polygenic score and cross-trait genetic analysis
    Azmeraw T. Amare, Klaus Oliver Schubert, Liping Hou, Scott Richard Clark, Sergi Papiol, Urs Heilbronner, Franziska Degenhardt, Fasil Tekola Ayele, Yi‐Hsiang Hsu, Tatyana Shekhtman et al. · 2017 · bioRxiv (Cold Spring Harbor Laboratory)
  46. Neurocognición y biomarcadores inflamatorios en primeros episodios psicóticos
    Bibiana Cabrera · 2017 · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
  47. Quels sont les biomarqueurs des phases précoces ?
    É. Fakra · 2019 · Troubles Psychotiques : Protocoles D'intervention Précoce
  48. Pronounced immunological abnormalities in unmedicated first episode as compared to chronic schizophrenia patients
    Berko Milleit, Jana Hesse, Kerstin Langbein, Kristin Rödiger, Christine Milleit, Ute‐Christiane Meier, Peter Ulrich Elsner, Uta‐Christina Hipler, Stefan Smesny · 2019 · Neurology Psychiatry and Brain Research
  49. Interaction between the immune and metabolic systems in different stages of schizophrenia spectrum disorders
    Roman Balõtšev · 2020 · DSpace repository (University of Tartu)
  50. Cardiovascular Manifestations in Schizophrenia
    Federica Calorio, Cristina Grazia Catania, Matteo Rocchetti · 2020 · Springer eBooks
  51. Anti-inflammatory Agents for Patients with Schizophrenia
    Nico J.M. van Beveren, Nuray Çakici, Iris E. Sommer · 2021 · Springer eBooks
  52. Microbiome-Gut-Brain Interactions in Neurodevelopmental Disorders: Focus on Autism and Schizophrenia
    Kiran V. Sandhu, Eoin Sherwin, Ted G. Dinan, John F. Cryan · 2021 · Cambridge University Press eBooks
  53. Mediadores inflamatórios em perfil pródromo de psicose como potenciais biomarcadores
    Cícero Augusto Costa Pereira · 2021
  54. Fingolimod ameliorates cognitive impairments in a phencyclidine-induced rat model of schizophrenia
    Tao Li, Xueli Yu, Xueyu Qi, Long Wei, Liansheng Zhao, Wei Deng, Wanjun Guo, Qiang Wang, Xiaohong Ma, Xun Hu et al. · 2022
  55. Cardiovascular Manifestations in Schizophrenia
    Federica Calorio, Cristina Grazia Catania, Matteo Rocchetti · 2020 · Springer eBooks
  56. FIRST-EPISODE PSYCHOSIS AND INFLAMMATION - WHAT DO WE KNOW?
    Marisa Martins, Nuno Fernandes, Núria F. Santos, Ricardo Gasparinho, L. Ferreira, Andre Ribeirinho Marques, António Palma Alho, João Martins Correia, Inês Fernandes · 2019
  57. Assessing cognitive reserve outcomes and biomarkers in first episode of psychosis: Rationale, objectives, protocol and preliminary results of the CRASH Project
    Miquel Bernardo, Gerard Anmella, Norma Verdolini, Cristina Saiz-Masvidal, Sonia Casals, Fernando Contreras, Ignasi Garrido, Ferran Pérez, Gemma Safont, Sergi Mas et al. · 2022 · Revista de Psiquiatría y Salud Mental
  58. Novel Approaches for Treating Psychotic Disorders
    Tiago Reis Marques, Shitij Kapur · 2017
  59. Targeting Metabolic Abnormalities in Mental Health Prevention Strategies
    Simone Schimmenti, Francesca Maria Camilla Maselli, Sarah Tosato · 2022 · Springer eBooks
  60. Fundamental disincorporation and early non-inflammatory microglia alterations: Possible bridging phenomena between neurobiology and psychopathology in schizophrenia
    Luca Magnani, Laura Fusar‐Poli, A. Parise, Khoa D. Nguyen, Danièle Saverino, Alessandra Costanza · 2023 · Medical Hypotheses
  61. The Differences in Adjuvant Therapy Effectiveness Meloxicam and N-Acetylcysteine against Negative Symptoms of Schizophrenia
    Banu Kadgada Kalingga Murda, I Gusti Bagus Indro Nugroho, Adriesti Herdaetha · 2023 · JUXTA Jurnal Ilmiah Mahasiswa Kedokteran Universitas Airlangga
  62. Esquizofrenia e Neuroinflamação: Uma revisão das pesquisas recentes que exploram as conexões entre a esquizofrenia e processos de neuroinflamação, abrindo caminho para novas estratégias terapêuticas.
    Verônica de Souza Martins, Natália Maria Riera Pimenta, Matheus Pereira Vieira, Gustavo de Godoi Teixeira, Victor Scaglioni Reis Brito · 2023 · Brazilian Journal of Implantology and Health Sciences
  63. Immunogenetic Factors in the Pathogenesis of Schizophrenia
    Maria Yu. Plotnikova, Кунижева Светлана Станиславовна, Elizaveta V. Rozhdestvenskikh, Т. В. Андреева · 2023 · Russian Journal of Genetics
  64. Más allá de lo habitual: Nuevos enfoques en la terapia de la esquizofrenia resistente
    Jesús Fernando Guzmán Castellanos, Mariana Rentería Jiménez, Andrés J. Bolaños-Chang, Assurian Mariett Zambrano Pelayo, Erendira Aracelis Cedeño Meza · 2023 · Archives of Evidence-Based Medicine
  65. Immunogenetic Factors in the Pathogenesis of Schizophrenia
    Maria Yu. Plotnikova, Кунижева Светлана Станиславовна, Elizaveta V. Rozhdestvenskikh, Т. В. Андреева · 2023 · Генетика
  66. Pilot Study to Detect the Repertoires of T-Cell Receptor Gamma Chains in Patients with Juvenile Schizophrenia
    Maria Yu. Plotnikova, A. D. Patrikeev, Аnastasia Levchenko, Olga Y. Fedorenko, Т. В. Андреева, Evgeny Ivanovich Rogaev · 2023 · Генетика
  67. Komorbide psychiatrische Erkrankungen
    Einar Thorsteinsson, Rhonda Frances Brown · 2024 · Springer eBooks
  68. Diet and Psychosis
    Yara Ghanem, Afnan A. Almarshedi, Marwa Adam Abdelrahman Adam, Mario Eid, Rūta Karaliūnienė, Sharad Philip, Samer El Hayek · 2024 · Nutritional neurosciences
  69. Differential associations between cytokine and complement proteins in the clinical high risk and first episode stages of psychosis: Blood based investigation across three international studies of psychosis: NEURAPRO, STEP and OPTiMiSE
    Subash Raj Susai, Rachel Davis, David Mongan, Melanie Föcking, Meike Heurich, Gerard Cagney, Joshua Gilheany, Jennifer Murphy, Mary D Cannon, Joseph F. Ward et al. · 2025 · Research Square
  70. Transforming Growth Factor-β Serum Levels Associated with Social Function in Subjects at Ultra-high Risk for Psychosis: A Multicenter Study
    Yuji Yamada, Naoko Kishimoto, Hiromi Tagata, Tsubasa Morimoto, Kazuho Tomimoto, Yutaro Sato, Yuko Higuchi, Hiroshi Hiejima, Hayato Ohshima, Takao Kato et al. · 2025 · Clinical Psychopharmacology and Neuroscience
  71. The Role of Psychoneuroimmunology in Mental Health Disorders
    Thaddeus Alfonso, Maharishi Ranganathan · 2025 · Advances in medical diagnosis, treatment, and care (AMDTC) book series
  72. The Role of Immunoinflammatory Factors in the Development of Negative Symptoms in Schizophrenia
    Alan R. Moritz, P. S. Terebova, Mikhail V. Ivanov · 2025 · Neuroscience and Behavioral Physiology
  73. Shared genetic basis for brain structure, insulin resistance and inflammation in schizophrenia: a colocalization study
    Amalie C. M. Couch, Benjamin Ian Perry, Daniel B. Rosoff, Edward R. Palmer, Jack C Rogers, David William Ray, Rachel Upthegrove · 2025 · Research Square
  74. The Pathobiological Underpinnings of Psychosis: From the Stress-Related Hypothesis to a Multisystemic Approach
    Evangelos Karanikas · 2025 · NeuroSci
  75. Effects of palmitoylethanolamide in clinical high-risk for psychosis: A nonrandomized open-label trial
    Riccardo Bortoletto, Marco Garzitto, Marta Basaldella, Claudia Scipioni, Orietta Sepulcri, Martina Fabris, Francesco Curcio, Matteo Balestrieri, Marco Colizzi · 2025 · Brain Behavior & Immunity - Health
  76. Neuropsychiatric Sequelae of Chronic Rhinosinusitis: A Retrospective Cohort Study Using a Multi-institutional Electronic Health Records Network
    Ioannis Zerefos, Zachary Li, Katherine M Napalinga · 2026 · Cureus
  77. Neuro-inflammation and Serum Cytokine Levels in Schizophrenia Patients
    Ahmed Abbas Barh Aljamah, Majid Komijani · 2025 · Academia Open
  78. PEPAMARKER: a multicenter cohort study protocol on predictive biomarkers of affective vs. non-affective trajectories in first-episode psychosis
    Raphaël Terrisse, Christophe Lemey, Deok-Hee Kim-Dufor, Louise Miglianico, Florian Stéphan · 2026 · Frontiers in Psychiatry
  79. Identification of metabolism and inflammation-related biomarkers and potential drugs for schizophrenia based on comprehensive bioinformatics and machine learning
    Yanfang Chen, Min Zhang, Ling Qiao, Feng Lu, Shaoping Ji · 2026 · BMC Psychiatry
  80. Bipolar Bozukluk Nedeniyle Lityum Kullanan Ve Yatarak Tedavi Edilen Ergenlerde İnflamatuar Belirteçlerin Tedavi Yanıtını Öngörmedeki Yeri
    Ayşegül Tonyalı, Binay Kayan Ocakoğlu, Esra Bulanık Koç, Omca Guney, Seda Demirci, Aslı Ece Soykut, Beyza Şallı, Şükret ALEV, Gül Karaçetin · 2026 · Bozok Tıp Dergisi
  81. TNF-α in schizophrenia: Associations with cholesterol and genetic variations
    Xue Xin Goh, Pek Yee Tang, Kok Yoon Chee, Shiau Foon Tee · 2026 · Journal of Neuroimmunology
  82. Longitudinal investigation of the T helper (Th)1-Th2 balance and complement system in clinical high risk for psychosis cohort
    T. Zhang, JinYang Zhao, XiaoChen Tang, Yanyan Wei, MingLiang Ju, D. H. Zhang, Yingying Tang, HuiRu Cui, ZhengHui Yi, XiaoHua Liu et al. · 2026 · Translational Psychiatry
  83. Inflammation, infections et maladies mentales : identification de biomarqueurs et applications thérapeutiques potentielles
    Guillaume B. Fond · 2016 · theses.fr (ABES)
  84. Impact of psychotomimetic molecules on glutamatergic N-Methyl-D-Aspartate receptors surface trafficking
    Julie Jézéquel · 2016 · theses.fr (ABES)
  85. Role of immune and nervous system interaction : pre-clinical and clinical studies
    Douglas Daoudlarian · 2018 · theses.fr (ABES)
  86. Physical exercise as a non-pharmacological adjunct in schizophrenia: Effects on molecular and biochemical parameters
    Gustavo Cassol, Mauren Assis Souza, Fernando da Silva Fiorin · 2026 · Brain Research
  87. Air pollution and the risk of schizophrenia: current evidence, mechanisms, and future directions
    Ruqi Zhou, Binghua Li, Jianhua Chen · 2026 · Reviews in the Neurosciences
  88. Clinical correlates and cognitive associations of the neutrophil-to-lymphocyte ratio in first-episode psychosis and at-risk mental states
    Clàudia Aymerich, Borja Pedruzo, Garazi Acasuso, Olatz Ibarretxe, Daniel Alonso Alconada, Javier Labad, María José Algora, Ángel Cabezas, Gonzalo Salazar de Pablo, Miguel Angel Gonzalez-Torres et al. · 2026 · Frontiers in Psychiatry
  89. Diagnostic utility of pan-immune inflammation value in drug-naïve first-episode psychosis
    Seda Kıraz, Ezgi Cellat, Bedirhan Şenol, Merve Eltemiz Yıldırım, Erol Göka · 2026 · International Journal of Psychiatry in Clinical Practice
  90. Sharp-Wave EEG Activity and Cytomegalovirus Exposure in Schizophrenia Spectrum Disorders: A Neuroimmune Perspective
    Mădălina Georgeta Sighencea, Marius Cornitescu, Simona Corina Trifu · 2026 · Journal of Clinical Medicine
  91. Protective Effects of Gallic Acid on Oxidative and Inflammatory Markers in the Hippocampus and Prefrontal Cortex of a Ketamine-Induced Schizophrenia-like Model
    Ali Osman Arslan, I. Cetin, Özgür Mehmet Yis, Sevdenur Uzun, Güven Akçay · 2026 · Brain Sciences
  92. The Effect of Microbiota and Evaluation of Released Cytokines in Schizophrenia Patients
    Demet Çelebi, Özgür Çelebi, Sümeyye Başer, Halil Özcan, Ali Taghizadehghalehjoughi, Ahmet Hacımüftüoğlu · 2026 · Current Microbiology
  93. Altered function of peripheral organ systems in first-episode drug naïve mental illnesses: A systematic review and meta-analysis
    Jetro Emanel Ang, Yangqi Xu, Vanessa Cropley, Andrew Zalesky, Ye Tian · 2026 · medRxiv
  94. Immunometabolic reprogramming of central and peripheral immune cells in mental disorders: mechanisms and therapeutic implications
    Kexin Lin, Peipei Wang, Shen Li, Chunling Ma, Di Wen, Xia Wang, Linchuan Liao · 2026 · Frontiers in Immunology
  95. Cytokines in First-Episode Psychosis: Implications for Pathophysiology: A Narrative Literature Review
    Lindokuhle T. Thela, Bongani Brian Nkambule, Zama N. P. Msibi, Vuyokazi Ntlantsana, Saeeda Paruk, Andrew M. Tomita, Khethelo Richman Xulu, Bonginkosi Chiliza · 2026 · Brain Sciences
  96. The role of persistent psychotic experiences in inflammation in childhood and adulthood
    Lorna Staines, Jennifer Murphy, Jonah F. Byrne, Lorenzo Ghelfi, Emmet Power, Subash Raj Susai, David Mongan, Colm Healy, Mary D Cannon, David Cotter · 2026 · Brain Behavior and Immunity
  97. Early-life inflammatory subgroups in youth with psychotic experiences: A semi-supervised machine learning approach.
    Shalini Bhattacharya, Kate Merritt, G. Khandaker, P. Lalousis, Anthony S. David · 2026 · Brain, behavior, and immunity
  98. Cytokine and C-reactive protein concentrations over 6 months of treatment with clozapine in treatment resistant schizophrenia
    Katherine Embleton, Sophie D. Bennett, James Hunter MacCabe, Alice Egerton · 2026 · Brain Behavior & Immunity - Health
  99. Schizophrenia: Converging Neurobiological Mechanisms and Emerging Therapeutic Strategies
    Chun-Mei Gong, Kun-Ze Liu, Peng Wang, Mu-Yan Wen, Jie Wang, Zhen-Ying Li, Wei-Jingyi Lu, Zi-Liang Wang, Li-Fang Lu, Renjun Feng · 2026 · Biomolecules
  100. Altered function of peripheral organ systems in first-episode drug naïve mental illnesses: a systematic review and meta-analysis
    Jetro Emanel Ang, Yangqi Xu, Vanessa Cropley, Andrew Zalesky, Ye Tian · 2026 · Molecular Psychiatry